<DOC>
	<DOC>NCT00560950</DOC>
	<brief_summary>The purpose of this study is to determine that revaccination of Pneumococcal Vaccine is well tolerated and produces an immune response in older adults.</brief_summary>
	<brief_title>Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)</brief_title>
	<detailed_description>This study is an extension study (V110-007-10) which met requirements for posting on clinicaltrials.gov. The original study (V110-007-00) was completed in 2004 and did not meet the criteria for registration.</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Postmenopausal or negative urine pregnancy test if female No fever on the day of vaccination History of allergy to vaccine components History of pneumococcal disease Received any live virus vaccination within 4 weeks prior to study start Received any inactivated vaccination within 7 days prior to study start Received any blood products within 5 months prior to study start Participated in an investigational drug or vaccine study in the past 30 days Received immunosuppressive therapy Patient has an immune deficiency</criteria>
	<gender>All</gender>
	<minimum_age>59 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>